1221443-94-2Relevant articles and documents
Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (a-1165442): A temperature-neutral transient receptor potential vanilloid-1 (trpv1) antagonist with analgesic efficacy
Voight, Eric A.,Gomtsyan, Arthur R.,Daanen, Jerome F.,Perner, Richard J.,Schmidt, Robert G.,Bayburt, Erol K.,Didomenico, Stanley,McDonald, Heath A.,Puttfarcken, Pamela S.,Chen, Jun,Neelands, Torben R.,Bianchi, Bruce R.,Han, Ping,Reilly, Regina M.,Franklin, Pamela H.,Segreti, Jason A.,Nelson, Richard A.,Su, Zhi,King, Andrew J.,Polakowski, James S.,Baker, Scott J.,Gauvin, Donna M.,Lewis, Lageisha R.,Mikusa, Joseph P.,Joshi, Shailen K.,Faltynek, Connie R.,Kym, Philip R.,Kort, Michael E.
, p. 7412 - 7424 (2014)
The synthesis and characterization of a series of selective, orally bioavailable 1-(chroman-4-yl)urea TRPV1 antagonists is described. Whereas first-generation antagonists that inhibit all modes of TRPV1 activation can elicit hyperthermia, the compounds disclosed herein do not elevate core body temperature in preclinical models and only partially block acid activation of TRPV1. Advancing the SAR of this series led to the eventual identification of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442, 52), an analogue that possesses excellent pharmacological selectivity, has a favorable pharmacokinetic profile, and demonstrates good efficacy against osteoarthritis pain in rodents.
TRPV1 ANTAGONISTS
-
Page/Page column 91, (2010/04/30)
Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.